Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc stock is traded at $8.15, with a volume of 24,102. It is down -0.49% in the last 24 hours and down -50.79% over the past month. Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.